Outcome of Board Meeting
The board of the Company has approved execution of the amended and restated shareholders' agreement on March 29, 2017, to be entered into amongst the Company and the promoter shareholders.29-03-2017
29-03-2017
Updates
In furtherance to the intimation captioned 'Update on US FDA Inspection at Alkem's Ankaleshwar API Facility' dated 12th December, 2016, this is to inform you that the US FDA has issued an Establishment Inspection Report (EIR) for the Company's Active Pharmaceutical Ingredient (API) manufacturing facility located at Ankaleshwar, India which was inspected in December 2016. The inspection has now been closed by the US FDA. In response to the Form...29-03-2017
Closure of Trading Window
This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 30th March, 2017 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and year ended 31st March, 2017 are communicated to the Stock Exchanges.29-03-2017
US FDA note: Setback likely for Alkem Lab
Shares of Alkem Laboratories may come under pressure on Tuesday on USFDA observations. In a notification to the stock exchanges, the company said USFDA had conducted an inspection at the company's...10-03-2017
Updates
Sub: Update on US FDA Inspection at Alkem's Baddi Facility This is to inform you that US FDA had conducted an inspection at the Company's manufacturing facility located at Baddi, India from 2nd March, 2017 to 10th March, 2017. In this regard, the Company has received the inspection report which contains three 483 observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the...10-03-2017
Alkem Laboratories is grabbing the Street's eyeballs
Good momentum in domestic sales and growing US business help stock movement08-03-2017
Alkem Laboratories Q3 profit rises 24.89% at Rs233 crore
Alkem Laboratories total income from operations during third quarter stood at Rs 1,481.92 crore as against Rs1,287.84 crore in the same quarter last fiscal, up 15%10-02-2017
Opening of Trading Window
Alkem Laboratories Ltd has informed BSE regarding "Opening of Trading Window"10-02-2017
Results Press Release, Result Presentation for December 31, 2016
Alkem Laboratories Ltd has informed BSE about : 1. Result Press Release for the period ended December 31, 20162. Result Presentation for the period ended December 31, 201610-02-2017
Standalone & Consolidated Financial Results, Limited Review Report for December 31, 2016
Alkem Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 20162. Consolidated Financial Results for the period ended December 31, 20163. Standalone Limited Review for the period ended December 31, 20164. Consolidated Limited Review for the period ended December 31, 201610-02-2017